SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SIGHINOLFI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.092
AS - Asia 1.788
EU - Europa 1.214
SA - Sud America 278
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.010
SG - Singapore 703
PL - Polonia 576
CN - Cina 372
VN - Vietnam 245
BR - Brasile 210
HK - Hong Kong 156
IT - Italia 124
DE - Germania 109
FI - Finlandia 89
GB - Regno Unito 83
ID - Indonesia 77
JP - Giappone 70
FR - Francia 56
RU - Federazione Russa 47
IN - India 41
SE - Svezia 37
CA - Canada 36
MX - Messico 35
BD - Bangladesh 31
AR - Argentina 25
ZA - Sudafrica 19
AT - Austria 18
NL - Olanda 18
ES - Italia 17
UA - Ucraina 16
IQ - Iraq 13
TR - Turchia 13
KE - Kenya 12
CO - Colombia 10
PH - Filippine 10
TH - Thailandia 9
VE - Venezuela 9
MA - Marocco 8
EC - Ecuador 7
PE - Perù 7
PK - Pakistan 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
IE - Irlanda 6
EG - Egitto 5
CL - Cile 4
LT - Lituania 4
MY - Malesia 4
PS - Palestinian Territory 4
BE - Belgio 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EU - Europa 3
IL - Israele 3
NP - Nepal 3
PY - Paraguay 3
TN - Tunisia 3
BH - Bahrain 2
CH - Svizzera 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
JO - Giordania 2
LB - Libano 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MD - Moldavia 1
MR - Mauritania 1
NO - Norvegia 1
OM - Oman 1
RO - Romania 1
RW - Ruanda 1
TG - Togo 1
TW - Taiwan 1
Totale 6.432
Salva come PNG Salva come JPEG
Città #
Warsaw 574
Ashburn 526
Singapore 405
Fairfield 331
San Jose 248
Santa Clara 211
Beijing 208
Hong Kong 153
Woodbridge 145
Seattle 134
Houston 118
Wilmington 113
Cambridge 101
Chandler 87
Jakarta 70
Tokyo 70
Ho Chi Minh City 67
Council Bluffs 65
Helsinki 63
Dallas 62
Los Angeles 55
Hanoi 54
Dong Ket 52
Lauterbourg 49
Princeton 46
Ann Arbor 36
New York 34
San Diego 34
Munich 31
São Paulo 25
London 24
Turku 24
Ferrara 23
Nuremberg 22
Washington 22
Bremen 20
Mexico City 19
Montreal 17
Orem 17
Shanghai 17
Buffalo 15
Chicago 15
Santa Maria Di Sala 14
Bologna 13
Frankfurt am Main 13
Brooklyn 12
Stockholm 12
Da Nang 11
Johannesburg 11
Milan 11
Portsmouth 11
Boston 10
Vienna 10
Chennai 9
Falls Church 9
Nairobi 9
Redwood City 9
The Dalles 9
Atlanta 8
Dhaka 8
Haiphong 7
Moscow 7
Padova 7
Shenzhen 7
Toronto 7
Belo Horizonte 6
Cape Town 6
San Francisco 6
Umeå 6
Utrecht 6
Boardman 5
Brasília 5
Can Tho 5
Denver 5
Guangzhou 5
Jacksonville 5
Mumbai 5
Poplar 5
Porto Alegre 5
Rio de Janeiro 5
Tianjin 5
Verona 5
Addison 4
Athens 4
Augusta 4
Birmingham 4
Blumenau 4
Charlotte 4
Chiswick 4
Des Moines 4
Dublin 4
Manchester 4
Medellín 4
Miami 4
Philadelphia 4
Rabat 4
Rome 4
Salt Lake City 4
Vancouver 4
Amsterdam 3
Totale 4.787
Salva come PNG Salva come JPEG
Nome #
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation 245
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 244
A Comparison Between Different Anti-Retroviral Therapy Regimes on Soluble Inflammation Markers: a Pilot Study 200
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 195
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 191
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 187
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 180
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 176
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 173
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 166
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 164
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 163
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 160
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 158
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 158
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 156
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 156
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 145
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 138
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 137
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 136
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 132
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 131
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 130
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 129
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 129
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 128
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 127
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 119
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 118
ANTIRETROVIRAL THERAPY RESTORES NAÏVE T CELL FREQUENCIES OC 8 AND FUNCTIONALITY IN PLWH 117
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 116
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 116
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 113
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 113
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 112
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 108
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 108
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 108
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 106
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 105
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 105
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 102
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 89
IMMUNOSENESCENCE FEATURES ARE PARTIALLY RESTORED BY ANTIRETROVIRAL THERAPY 88
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 88
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 85
null 46
Totale 6.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.141
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.141
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 0 0 0 0 0 0 0 19 97
2021/2022339 41 18 2 5 15 44 21 27 16 39 12 99
2022/2023252 47 10 9 11 44 25 10 36 34 2 16 8
2023/2024334 14 27 29 14 46 91 11 7 5 3 2 85
2024/20251.130 25 11 115 25 138 140 32 36 175 157 148 128
2025/20262.679 290 106 246 258 419 185 423 134 287 318 13 0
Totale 6.596